News

Fabhalta® (iptacopan capsules), first oral treatment for adult patients with PNH, now available in Canada
Novartis Canada is pleased to announce that Fabhalta® (iptacopan capsules) is now available across Canada for adult patients ...
Yahoo Finance28d
Fabhalta Shakes Up the PNH Market in 15 Months as Soliris, Ultomiris, and Empaveli Compete and Voydeya and PiaSky Carve Their Niche
The competitive landscape for PNH has seen significant shifts, particularly with the introduction of Fabhalta (Novartis), which launched in December 2023, alongside newer market entrants Voydeya ...
FiercePharma25d
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
C3G marks Fabhalta’s third U.S. indication, following its approval in paroxysmal nocturnal hemoglobinuria (PNH) in 2023 and IgA nephropathy (IgAN) last year. “It’s a molecule nephrologists a ...
Seeking Alpha12d
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA ...
FABHALTA Indications FABHALTA is a prescription medicine used to: Treat adults with paroxysmal nocturnal hemoglobinuria (PNH). Reduce protein in the urine (proteinuria) in adults with a kidney ...
The American Journal of Managed Care25d
FDA Approves Oral Iptacopan for C3 Glomerulopathy
Iptacopan is also approved for paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy, with ongoing studies in other kidney conditions. Iptacopan's (Fabhalta; Novartis ...
Medindia25d
Novartis receives third FDA approval for oral Fabhalta (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis Media Relations E-mail: [email protected] Novartis Investor Relations Central investor relations line: +41 61 ...
The Bakersfield Californian28d
Fabhalta Shakes Up the PNH Market in 15 Months as Soliris, Ultomiris, and Empaveli Compete and ...
EXTON, PA, March 18, 2025 (GLOBE NEWSWIRE) -- Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and debilitating blood disorder that affects approximately 8,000 to 10,000 people in North America ...
Yahoo Finance28d
Fabhalta Shakes Up the PNH Market in 15 Months as Soliris, Ultomiris, and Empaveli Compete and Voydeya and PiaSky Carve Their Niche
The competitive landscape for PNH has seen significant shifts, particularly with the introduction of Fabhalta (Novartis), which launched in December 2023, alongside newer market entrants Voydeya ...